Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

693 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation.
van Zonneveld M, Flink HJ, Verhey E, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Hansen BE, Schalm SW, Janssen HL; HBV 99-01 Study Group. van Zonneveld M, et al. Among authors: gerken g. Aliment Pharmacol Ther. 2005 May 1;21(9):1163-71. doi: 10.1111/j.1365-2036.2005.02453.x. Aliment Pharmacol Ther. 2005. PMID: 15854180 Clinical Trial.
Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients.
Buster EH, Flink HJ, Simsek H, Heathcote EJ, Sharmila S, Kitis GE, Gerken G, Buti M, de Vries RA, Verhey E, Hansen BE, Janssen HL. Buster EH, et al. Among authors: gerken g. Am J Gastroenterol. 2009 Oct;104(10):2449-57. doi: 10.1038/ajg.2009.371. Epub 2009 Jul 7. Am J Gastroenterol. 2009. PMID: 19584831 Clinical Trial.
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW; HBV 99-01 Study Group; Rotterdam Foundation for Liver Research. Janssen HL, et al. Among authors: gerken g. Lancet. 2005 Jan 8-14;365(9454):123-9. doi: 10.1016/S0140-6736(05)17701-0. Lancet. 2005. PMID: 15639293 Clinical Trial.
Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial.
Orlent H, Hansen BE, Willems M, Brouwer JT, Huber R, Kullak-Ublick GA, Gerken G, Zeuzem S, Nevens F, Tielemans WC, Zondervan PE, Lagging M, Westin J, Schalm SW. Orlent H, et al. Among authors: gerken g. J Hepatol. 2006 Oct;45(4):539-46. doi: 10.1016/j.jhep.2006.05.015. Epub 2006 Jun 30. J Hepatol. 2006. PMID: 16905220 Clinical Trial.
Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C.
Veldt BJ, van der Vliet HJ, von Blomberg BM, van Vlierberghe H, Gerken G, Nishi N, Hayashi K, Scheper RJ, de Knegt RJ, van den Eertwegh AJ, Janssen HL, van Nieuwkerk CM. Veldt BJ, et al. Among authors: gerken g. J Hepatol. 2007 Sep;47(3):356-65. doi: 10.1016/j.jhep.2007.04.018. Epub 2007 Jun 6. J Hepatol. 2007. PMID: 17599630 Clinical Trial.
Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP).
Janssen HL, Gerken G, Carreño V, Marcellin P, Naoumov NV, Craxi A, Ring-Larsen H, Kitis G, van Hattum J, de Vries RA, Michielsen PP, ten Kate FJ, Hop WC, Heijtink RA, Honkoop P, Schalm SW. Janssen HL, et al. Among authors: gerken g. Hepatology. 1999 Jul;30(1):238-43. doi: 10.1002/hep.510300113. Hepatology. 1999. PMID: 10385662 Clinical Trial.
The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep).
Krogsgaard K, Bindslev N, Christensen E, Craxi A, Schlichting P, Schalm S, Carreno V, Trepo C, Gerken G, Thomas HC, et al. Krogsgaard K, et al. Among authors: gerken g. J Hepatol. 1994 Oct;21(4):646-55. doi: 10.1016/s0168-8278(94)80114-2. J Hepatol. 1994. PMID: 7814812
FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.
Patel K, Friedrich-Rust M, Lurie Y, Grigorescu M, Stanciu C, Lee CM, Schiff ER, Häussinger D, Manns MP, Gerken G, Colle I, Torbenson M, Pulkstenis E, Subramanian GM, McHutchison JG, Zeuzem S. Patel K, et al. Among authors: gerken g. World J Gastroenterol. 2011 Nov 7;17(41):4581-9. doi: 10.3748/wjg.v17.i41.4581. World J Gastroenterol. 2011. PMID: 22147963 Free PMC article. Clinical Trial.
693 results